NCT06632977Toboroz2. fázis
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. nov. 3.
Rövid összefoglaló (regiszter, angolul)
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 2. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 474 (tervezett)
- Első benyújtás
- 2024. okt. 1.
- Kezdés
- 2025. febr. 6.
- Elsődleges befejezés
- 2030. ápr. 11.
- Fő szponzor
- Alliance for Clinical Trials in Oncology
- Betegségek
- Prosztatarák
- NCT-szám
- NCT06632977
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 2. fázis
- Tervezett résztvevők: 474
- 2025. febr. 6. és az elsődleges befejezés (2030. ápr. 11.) között
- 108 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Kiket keres a vizsgálat
- PRE-REGISTRATION: Measurable disease and/or non-measurable metastatic disease per RECIST version 1.1.
- PRE-REGISTRATION: Tissue procured within 12 months of pre-registration (metastatic disease preferred over primary tissue, though both are acceptable) available for submission per Section 6.2. For patients who have progressed on A032102 and are pre-registering again, repeat tissue procurement will not be mandated.
- PRE-REGISTRATION: Molecular report available performed as part of standard of care testing via any Clinical Laboratory Improvement Act (CLIA)-certified next generation sequencing (NGS) assay. Patients may be assigned based on pre-determined qualifying molecular/DNA alterations as stated in Section 4.8 after receipt of local molecular testing by the A032102 molecular tumor board (MTB). Final determination of arm assignment will be determined by the MTB. For qualifying DNA alteration determined by the MTB, testing may be from tumor tissue collected at any time or circulating tumor DNA (ctDNA) within 12 months of pre-registration. If no qualifying DNA alteration is identified based on the CLIA-certified next generation sequencing assay and MTB review, Caris testing, should be performed for both DNA/RNA profiling. Arm assignment based RNA requires testing of tumor tissue collected within 12 months of pre-registration and MTB review.
- PRE-REGISTRATION: Age ≥ 18 years.
- REGISTRATION: Progressive mCRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND one or more of the following criteria (choose all the apply): * PSA progression, defined by at least 2 consecutive rising PSA values at a minimum of 1-week intervals with the most recent PSA value being 2.0 ng/mL or higher, if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen must have PSA progression after withdrawal of anti-androgen therapy. * Radiographic progression per RECIST 1.1 criteria for soft tissue lesions * Bone metastasis progression per Prostate Cancer Working Group 3 (PCWG3) criteria.
- REGISTRATION: Patients selected to receive lutetium Lu 177 vipivotide tetraxetan treatment are required to have prostate-specific membrane antigen (PSMA) positive mCRPC as determined by investigator assessment. For reference, in the VISION trial this was defined as at least 1 PSMA+ metastatic lesion (defined as uptake greater than that of liver parenchyma in lesions of any size in any organ system) and no PSMA- lesions (defined as uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any solid organ lesion with a short axis of at least 1.0 cm, or in any bone lesion with a soft-tissue component of at least 1.0 cm in the short axis).
- REGISTRATION: Prior treatment with androgen receptor signaling inhibitor (ARSI) in either the metastatic hormone sensitive setting or mCRPC is required. Prior taxane therapy in either metastatic hormone sensitive setting or mCRPC is mandated unless patient is taxane ineligible or the patient refuses taxane therapy. Prior lutetium LU177 vipivotide tetraxetan treatment is permitted but not mandated. Patients with known germline or somatic deleterious BRCA 1/2 mutations must have received a prior PARPi.
- REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo)
- REGISTRATION: No cytotoxic, biologic, radiopharmaceutical or other non-kinase inhibitor investigational agent within 4 weeks of registration. Treatment with any type of small molecular kinase inhibitor (including investigational kinase inhibitor) within 2 weeks of registration. Treatment with abiraterone acetate, apalutamide, or darolutamide within 2 weeks of registration. Treatment with enzalutamide within 4 weeks of registration. No treatment with radiation therapy within 2 weeks of registration.
- REGISTRATION: No major surgery within 4 weeks of registration.
- REGISTRATION: No prior treatment with EZH inhibitors.
- REGISTRATION: Prior treatment with cabazitaxel + carboplatin.
- REGISTRATION: None of the following conditions: * Current use of moderate or strong cytochrome P450 (CYP)3A inducers. * Known or suspected hypersensitivity to valemetostat tosylate (DS-3201b) or any of the excipients. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before registration. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) ≥ 470 ms per electrocardiogram (ECG) within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. Patients with known history or current symptoms of cardiac disease, history of treatment with cardiotoxic agents, or agents/conditions known to impact QTcF should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and ECG. * Uncontrolled hypertension (resting systolic blood pressure \>160 mmHg or diastolic blood pressure \> 100 mmHg). * Clinically significant acute infection requiring systemic antibacterial, antifungal or antiviral therapy. * Moderate to severe hepatic impairment (Child-Pugh Class C)
- REGISTRATION: No freezing or donating sperm ≤ 14 days prior to registration.
- REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- REGISTRATION: No granulocyte colony-stimulating factor (GCSF) within 2 weeks of registration.
- REGISTRATION: No red blood cell (RBC) transfusions within 2 weeks of registration.
- REGISTRATION: No platelet transfusions within 2 weeks of registration.
- REGISTRATION: No bleeding diathesis.
- REGISTRATION: White blood cell count (WBC) ≥ 2,500/mcL.
- REGISTRATION: Absolute neutrophil count (ANC) ≥ 1,500/mcL.
- REGISTRATION: Hemoglobin ≥ 9 g/dL.
- REGISTRATION: Platelet count ≥ 100,000/mcL.
- REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation.
- REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x upper limit of normal [ULN] for subjects with documented Gilbert\'s disease).
- REGISTRATION: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
- REGISTRATION: Albumin ≥ 2.8 g/dL.
- REGISTRATION: The A032102 molecular tumor board will review the local pathology report and molecular sequencing report, and the Alliance registration/randomization office will relay the assignment to the submitting site. Once the site receives this assignment, they can register the patient to A032102. Any questions about the molecular board treatment assignments can be directed to.
- RE-REGISTRATION: Progressive mCRPC (after receiving the tumor board assigned therapy) as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease defined by radiographic progression on conventional imaging (CT/MRI chest, abdomen and pelvis and bone scan within 42 days of re-registration).
- RE-REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to CTCAE version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo).
- RE-REGISTRATION: None of the following conditions: * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to re-registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before re-registration. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) \< 470 ms per ECG within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Uncontrolled hypertension (resting systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg).
- RE-REGISTRATION: ECOG Performance Status 0-2.
- RE-REGISTRATION: No GCSF within 2 weeks of registration.
- RE-REGISTRATION: No RBC transfusions within 2 weeks of registration.
- RE-REGISTRATION: No platelet transfusions within 2 weeks of registration.
- RE-REGISTRATION: WBC ≥ 2,500/mcL.
- RE-REGISTRATION: ANC ≥ 1,500/mcL.
- RE-REGISTRATION: Hemoglobin ≥ 9 g/dL (transfusions permitted).
- RE-REGISTRATION: Platelet count ≥ 100,000/mcL.
- RE-REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation.
- RE-REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for subjects with documented Gilbert\'s disease).
- RE-REGISTRATION: AST and ALT ≤ 3 x ULN.
- RE-REGISTRATION: Albumin ≥ 2.8 g/dL.
- RE-REGISTRATION: QT Interval (QTcF) \< 470 ms (in individuals with any cardiac history of any medication or condition known to impact QTcF).
- RE-REGISTRATION: The A032102 molecular tumor board will review the CARIS molecular sequencing report, the Alliance registration/randomization office will relay the assignment to the site. Any questions about the molecular board treatment assignments can be directed to. Exclusion Criteria: -
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (108)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| McFarland Clinic - Ames | Ames | Egyesült Államok | Toboroz |
| University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf | Egyesült Államok | Toboroz |
| Billings Clinic Cancer Center | Billings | Egyesült Államok | Toboroz |
| University of Alabama at Birmingham Cancer Center | Birmingham | Egyesült Államok | Toboroz |
| Illinois CancerCare-Bloomington | Bloomington | Egyesült Államok | Toboroz |
| Dana-Farber Cancer Institute | Boston | Egyesült Államok | Felfüggesztve |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Egyesült Államok | Toboroz |
| Roswell Park Cancer Institute | Buffalo | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Egyesült Államok | Toboroz |
| Illinois CancerCare-Canton | Canton | Egyesült Államok | Toboroz |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | Egyesült Államok | Toboroz |
| Vandalia Health/CAMC Institute for Academic Medicine | Charleston | Egyesült Államok | Fut, nem toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Egyesült Államok | Toboroz |
| Enloe Medical Center | Chico | Egyesült Államok | Toboroz |
| Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters | Egyesült Államok | Toboroz |
| MetroHealth Medical Center | Cleveland | Egyesült Államok | Toboroz |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Egyesült Államok | Felfüggesztve |
| Memorial Hospital North | Colorado Springs | Egyesült Államok | Toboroz |
| UCHealth Memorial Hospital Central | Colorado Springs | Egyesült Államok | Toboroz |
| MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia | Egyesült Államok | Fut, nem toboroz |
| Ohio State University Comprehensive Cancer Center | Columbus | Egyesült Államok | Toboroz |
| Siteman Cancer Center at West County Hospital | Creve Coeur | Egyesült Államok | Toboroz |
| UT Southwestern Simmons Cancer Center - RedBird | Dallas | Egyesült Államok | Toboroz |
| Parkland Memorial Hospital | Dallas | Egyesült Államok | Felfüggesztve |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Egyesült Államok | Toboroz |
| Carle at The Riverfront | Danville | Egyesült Államok | Toboroz |
| Essentia Health Cancer Center | Duluth | Egyesült Államok | Toboroz |
| Saint Elizabeth Healthcare Edgewood | Edgewood | Egyesült Államok | Toboroz |
| Swedish Cancer Institute-Edmonds | Edmonds | Egyesült Államok | Toboroz |
| Carle Physician Group-Effingham | Effingham | Egyesült Államok | Toboroz |
| UC San Diego Health System - Encinitas | Encinitas | Egyesült Államok | Toboroz |
| Illinois CancerCare-Eureka | Eureka | Egyesült Államok | Toboroz |
| Essentia Health Cancer Center-South University Clinic | Fargo | Egyesült Államok | Toboroz |
| Poudre Valley Hospital | Fort Collins | Egyesült Államok | Toboroz |
| Cancer Care and Hematology-Fort Collins | Fort Collins | Egyesült Államok | Toboroz |
| Saint Elizabeth Healthcare Fort Thomas | Fort Thomas | Egyesült Államok | Felfüggesztve |
| UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth | Egyesült Államok | Toboroz |
| Dana-Farber Cancer Institute at Foxborough | Foxborough | Egyesült Államok | Toboroz |
| Gibbs Cancer Center-Gaffney | Gaffney | Egyesült Államok | Toboroz |
| UCHealth Greeley Hospital | Greeley | Egyesült Államok | Toboroz |
| Gibbs Cancer Center-Pelham | Greer | Egyesült Államok | Toboroz |
| Hackensack University Medical Center | Hackensack | Egyesült Államok | Toboroz |
| Tripler Army Medical Center | Honolulu | Egyesült Államok | Toboroz |
| Edwards Comprehensive Cancer Center | Huntington | Egyesült Államok | Toboroz |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Egyesült Államok | Toboroz |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | Egyesült Államok | Fut, nem toboroz |
| Jupiter Medical Center | Jupiter | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center | Kansas City | Egyesült Államok | Toboroz |
| UC San Diego Moores Cancer Center | La Jolla | Egyesült Államok | Toboroz |
| University of Michigan Health - Sparrow Lansing | Lansing | Egyesült Államok | Toboroz |
| Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Egyesült Államok | Toboroz |
| Medical Center of the Rockies | Loveland | Egyesült Államok | Toboroz |
| Marshfield Medical Center-Marshfield | Marshfield | Egyesült Államok | Toboroz |
| Carle Physician Group-Mattoon/Charleston | Mattoon | Egyesült Államok | Toboroz |
| Bon Secours Memorial Regional Medical Center | Mechanicsville | Egyesült Államok | Toboroz |
| Froedtert Menomonee Falls Hospital | Menomonee Falls | Egyesült Államok | Toboroz |
| Dana Farber-Merrimack Valley | Methuen | Egyesült Államok | Toboroz |
| Bon Secours Saint Francis Medical Center | Midlothian | Egyesült Államok | Toboroz |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional | Milford | Egyesült Államok | Toboroz |
| Beebe South Coastal Health Campus | Millville | Egyesült Államok | Toboroz |
| Medical College of Wisconsin | Milwaukee | Egyesült Államok | Toboroz |
| Vanderbilt University/Ingram Cancer Center | Nashville | Egyesült Államok | Felfüggesztve |
| Medical Oncology Hematology Consultants PA | Newark | Egyesült Államok | Toboroz |
| Helen F Graham Cancer Center | Newark | Egyesült Államok | Toboroz |
| Mount Sinai Hospital | New York | Egyesült Államok | Toboroz |
| Drexel Town Square Health Center | Oak Creek | Egyesült Államok | Toboroz |
| Cancer Care Center of O'Fallon | O'Fallon | Egyesült Államok | Toboroz |
| University of Oklahoma Health Sciences Center | Oklahoma City | Egyesült Államok | Toboroz |
| The University of Kansas Cancer Center - Olathe | Olathe | Egyesült Államok | Toboroz |
| UC Irvine Health- Chao Family Comprehensive Cancer Center | Orange | Egyesült Államok | Fut, nem toboroz |
| Illinois CancerCare-Ottawa Clinic | Ottawa | Egyesült Államok | Toboroz |
| University of Kansas Hospital-Indian Creek Campus | Overland Park | Egyesült Államok | Toboroz |
| Illinois CancerCare-Pekin | Pekin | Egyesült Államok | Toboroz |
| Illinois CancerCare-Peoria | Peoria | Egyesült Államok | Toboroz |
| Illinois CancerCare-Peru | Peru | Egyesült Államok | Toboroz |
| Providence Saint Vincent Medical Center | Portland | Egyesült Államok | Toboroz |
| Providence Portland Medical Center | Portland | Egyesült Államok | Toboroz |
| Oregon Health and Science University | Portland | Egyesült Államok | Toboroz |
| Beebe Health Campus | Rehoboth Beach | Egyesült Államok | Toboroz |
| UT Southwestern Clinical Center at Richardson/Plano | Richardson | Egyesült Államok | Toboroz |
| VCU Massey Comprehensive Cancer Center | Richmond | Egyesült Államok | Toboroz |
| Bon Secours Richmond Community Hospital | Richmond | Egyesült Államok | Toboroz |
| Bon Secours Cancer Institute at Reynolds Crossing | Richmond | Egyesült Államok | Toboroz |
| VCU Massey Cancer Center at Stony Point | Richmond | Egyesült Államok | Toboroz |
| Bon Secours Saint Mary's Hospital | Richmond | Egyesült Államok | Toboroz |
| University of California Davis Comprehensive Cancer Center | Sacramento | Egyesült Államok | Toboroz |
| Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud | Egyesült Államok | Toboroz |
| UC San Diego Medical Center - Hillcrest | San Diego | Egyesült Államok | Toboroz |
| Guthrie Medical Group PC-Robert Packer Hospital | Sayre | Egyesült Államok | Fut, nem toboroz |
| Swedish Medical Center-First Hill | Seattle | Egyesült Államok | Toboroz |
| Memorial Hospital East | Shiloh | Egyesült Államok | Toboroz |
| Dana-Farber/Brigham and Women's Cancer Center at South Shore | South Weymouth | Egyesült Államok | Toboroz |
| Spartanburg Medical Center | Spartanburg | Egyesült Államok | Toboroz |
| Baystate Medical Center | Springfield | Egyesült Államok | Toboroz |
| Stamford Hospital/Bennett Cancer Center | Stamford | Egyesült Államok | Toboroz |
| Washington University School of Medicine | St Louis | Egyesült Államok | Toboroz |
| Siteman Cancer Center at Christian Hospital | St Louis | Egyesült Államok | Toboroz |
| Siteman Cancer Center-South County | St Louis | Egyesült Államok | Toboroz |
| University of Kansas Health System Saint Francis Campus | Topeka | Egyesült Államok | Toboroz |
| Banner University Medical Center - Tucson | Tucson | Egyesült Államok | Toboroz |
| University of Arizona Cancer Center-North Campus | Tucson | Egyesült Államok | Toboroz |
| SMC Center for Hematology Oncology Union | Union | Egyesült Államok | Toboroz |
| Carle Cancer Center | Urbana | Egyesült Államok | Toboroz |
| Illinois CancerCare - Washington | Washington | Egyesült Államok | Toboroz |
| Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Egyesült Államok | Toboroz |
| University of Kansas Hospital-Westwood Cancer Center | Westwood | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Egyesült Államok | Toboroz |
Kapcsolódó publikációk
- Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.JCO Precis Oncol · 2026 · PMID 41785440
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.